reported that in PDAC patients, high MUC16 protein expression correlates with faster tumor progression, more metastasis, aggressive subtypes like basal-like and squamous tumors, and shorter survival, with its abnormally glycosylated form activating AKT and GSK3β signaling pathways, thereby exacerbating tumor malignancy (65). Here, AKT1 is linked to neoplasm.